001449034 000__ 03183cam\a2200457\a\4500
001449034 001__ 1449034
001449034 003__ OCoLC
001449034 005__ 20230310004339.0
001449034 006__ m\\\\\o\\d\\\\\\\\
001449034 007__ cr\un\nnnunnun
001449034 008__ 220829s2022\\\\sz\\\\\\o\\\\\000\0\eng\d
001449034 020__ $$a9783031121845$$q(electronic bk.)
001449034 020__ $$a3031121848$$q(electronic bk.)
001449034 020__ $$z303112183X
001449034 020__ $$z9783031121838
001449034 0247_ $$a10.1007/978-3-031-12184-5$$2doi
001449034 035__ $$aSP(OCoLC)1342534829
001449034 040__ $$aYDX$$beng$$cYDX$$dGW5XE$$dEBLCP$$dOCLCF$$dOCLCQ
001449034 049__ $$aISEA
001449034 050_4 $$aRM315
001449034 08204 $$a615.7/8$$223/eng/20220901
001449034 24500 $$aDisruptive psychopharmacology /$$cFrederick S. Barrett, Katrin H. Preller, editors.
001449034 260__ $$aCham, Switzerland :$$bSpringer,$$c2022.
001449034 300__ $$a1 online resource.
001449034 4901_ $$aCurrent topics in behavioral neurosciences ;$$vv. 56
001449034 5050_ $$aDosing psychedelics and MDMA -- Psychedelic Group Therapy -- Set and Setting: Aesthetic experiences and their contribution to psychedelic therapies -- Psychedelic-Assisted Therapy for Social Adaptability in Autistic Adults -- Foundations for Training Psychedelic Therapists -- Ayahuasca for the Treatment of Depression -- Psilocybin for the Treatment of Depression -- Ketamine for the Treatment of Depression -- The Potential of Psychedelics for End of Life and Palliative Care -- Psychedelic-Assisted Therapy for Addiction and Potential Mechanisms of Action -- Psilocybin for Tobacco Use Disorder -- Psychedelic Drugs as Anti-Inflammatory Agents -- Psilocybin for the Treatment of Obsessive-Compulsive Disorder -- Psilocybin for the Treatment of Headache and Pain Disorders -- Psilocybin for the Treatment of Neurodegenerative Disorders -- Psilocybin for Trauma-Related Disorders.
001449034 506__ $$aAccess limited to authorized users.
001449034 520__ $$aPsychedelic therapies are gaining traction as potential treatments for a wide range of indications, but the structure and delivery of psychedelic therapies are a sharp departure from more traditional models of psychotherapy and pharmacotherapy for psychiatric and other medical disorders. This may be critical to their success. The current volume provides a comprehensive review of the state of the science of psychedelic therapies, including discussion of models and approaches to psychedelic therapies as well as the current status of safety and efficacy data for mood, substance use, trauma, obsessive-compulsive, neurodevelopmental, neurodegenerative disorders, neurological, and inflammatory disorders.
001449034 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed September 1, 2022).
001449034 650_0 $$aPsychopharmacology.
001449034 655_0 $$aElectronic books.
001449034 7001_ $$aBarrett, Frederick S.$$eeditor.
001449034 7001_ $$aPreller, Katrin H.$$eeditor.
001449034 77608 $$iPrint version: $$z303112183X$$z9783031121838$$w(OCoLC)1332780799
001449034 830_0 $$aCurrent topics in behavioral neurosciences ;$$vv. 56.
001449034 852__ $$bebk
001449034 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-12184-5$$zOnline Access$$91397441.1
001449034 909CO $$ooai:library.usi.edu:1449034$$pGLOBAL_SET
001449034 980__ $$aBIB
001449034 980__ $$aEBOOK
001449034 982__ $$aEbook
001449034 983__ $$aOnline
001449034 994__ $$a92$$bISE